DM926
/ D2M biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 27, 2023
DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models
(SITC 2023)
- "DM926 exhibited excellent stability in vitro and in vivo. The data warranted further development of DM926 as an immunotherapeutic for solid malignancies."
IO biomarker • Preclinical • Oncology • Solid Tumor • CD8 • IL10 • LILRB1 • TNFA
1 to 1
Of
1
Go to page
1